Investment Thesis
MiMedx exhibits strong top-line growth (20% YoY) and excellent gross margins (70.6%), but the company is unprofitable with -$16.0M operating income and -$10.9M net loss, indicating severe operational inefficiency. While the balance sheet is fortress-like with $159.8M cash and minimal debt (0.07x D/E), negative free cash flow of -$108K suggests the business model is structurally unviable at current cost levels, risking cash depletion despite strong financial position.
Strengths
- Revenue growth of 20% YoY demonstrates market traction and demand
- Exceptional gross margin of 70.6% shows strong pricing power and production efficiency
- Fortress balance sheet: $159.8M cash, 5.39x current ratio, 0.07x debt-to-equity ratio provides significant runway for operational turnaround
Risks
- Operating losses of -$16.0M (operating margin -27.2%) despite positive gross profit indicate bloated operating expenses and poor cost management
- Negative free cash flow (-$108K) on $59M revenue means business is unprofitable and unsustainable; cash depletion is inevitable without profitability improvement
- Negative ROE (-4.5%) and ROA (-3.5%) demonstrate capital is not generating returns; growth strategy is destroying shareholder value
Key Metrics to Watch
- Operating margin trajectory—must trend toward positive to validate turnaround thesis
- Free cash flow breakeven—critical inflection point; sustained negative FCF is death spiral indicator
- Cash burn rate and cash runway—calculate monthly burn; at current rate, determine months until depletion without additional action
Financial Metrics
Revenue
59.0M
Net Income
-10.9M
EPS (Diluted)
$-0.07
Free Cash Flow
-108.0K
Total Assets
308.7M
Cash
159.8M
Profitability Ratios
Gross Margin
70.6%
Operating Margin
-27.2%
Net Margin
-18.4%
ROE
-4.5%
ROA
-3.5%
FCF Margin
-0.2%
Balance Sheet & Liquidity
Current Ratio
5.39x
Quick Ratio
4.81x
Debt/Equity
0.07x
Debt/Assets
21.3%
Interest Coverage
-47.34x
Long-term Debt
16.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T15:42:38.469053 |
Data as of: 2026-03-31 |
Powered by Claude AI